Quantcast
AstraZeneca’s diabetes drug study shows benefit in adolescents – Metro US

AstraZeneca’s diabetes drug study shows benefit in adolescents

Exterior photos of the North America headquarters of AstraZeneca
Exterior photos of the North America headquarters of AstraZeneca

(Reuters) -AstraZeneca Plc’s diabetes drug significantly reduced blood sugar levels in adolescents aged 10–17 with type 2 diabetes in a late-stage study, the UK-based drugmaker said on Friday.

In type 2 diabetes, the body cannot properly use or make enough of the hormone insulin to convert blood sugar into energy.

In the study, patients who received once-weekly dose of exenatide, sold as Bydureon by AstraZeneca, showed significantly reduced levels of HbA1c – a measure of average blood sugar – from baseline at 24 weeks compared to placebo.

Exenatide is already approved in the United States for adult patients with type 2 diabetes.

Data from the study was presented at the 2021 American Diabetes Association (ADA) Virtual 81st Scientific Sessions.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

More from our Sister Sites